These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 34993499)

  • 21. Use of Open-Source Automated Insulin Delivery Systems in Pregnancies With Type 1 Diabetes.
    Sobhani NC; Killion M; Patzek S
    J Diabetes Sci Technol; 2023 Jul; 17(4):1126-1128. PubMed ID: 37062960
    [No Abstract]   [Full Text] [Related]  

  • 22. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy.
    Orban T; Farkas K; Jalahej H; Kis J; Treszl A; Falk B; Reijonen H; Wolfsdorf J; Ricker A; Matthews JB; Tchao N; Sayre P; Bianchine P
    J Autoimmun; 2010 Jun; 34(4):408-15. PubMed ID: 19931408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In Vivo Insulin Peptide Autoantigen Delivery by Mannosylated Sodium Alginate Nanoparticles Delayed but Could Not Prevent the Onset of Type 1 Diabetes in Nonobese Diabetic Mice.
    Qu Y; Shi H; Liu M; Zhang M; Wang H; Pang L; Zhang C; Kong D; Li C
    Mol Pharm; 2021 Apr; 18(4):1806-1818. PubMed ID: 33734705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autoantigen based vaccines for type 1 diabetes.
    Nicholas D; Odumosu O; Langridge WH
    Discov Med; 2011 Apr; 11(59):293-301. PubMed ID: 21524383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adequate doses of autoantigen administered using the appropriate route may create tolerance and stop autoimmunity.
    Ludvigsson J
    Diabetologia; 2009 Jan; 52(1):175-6. PubMed ID: 19005640
    [No Abstract]   [Full Text] [Related]  

  • 26. Oral delivery of bi-autoantigens by bacterium-like particles (BLPs) against autoimmune diabetes in NOD mice.
    Mao R; Wang J; Xu Y; Wang Y; Wu M; Mao L; Chen Y; Li D; Zhang T; Diao E; Chi Z; Wang Y; Chang X
    Drug Deliv; 2023 Dec; 30(1):2173339. PubMed ID: 36719009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extended Use of an Open-Source Automated Insulin Delivery System in Children and Adults with Type 1 Diabetes: The 24-Week Continuation Phase Following the CREATE Randomized Controlled Trial.
    Burnside MJ; Lewis DM; Crocket HR; Meier RA; Williman JA; Sanders OJ; Jefferies CA; Faherty AM; Paul RG; Lever CS; Price SKJ; Frewen CM; Jones SD; Gunn TC; Lampey C; Wheeler BJ; de Bock MI
    Diabetes Technol Ther; 2023 Apr; 25(4):250-259. PubMed ID: 36763345
    [No Abstract]   [Full Text] [Related]  

  • 28. Autoantigen-specific memory CD4+ T cells are prevalent early in progression to Type 1 diabetes.
    Oling V; Reijonen H; Simell O; Knip M; Ilonen J
    Cell Immunol; 2012; 273(2):133-9. PubMed ID: 22270037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antigen-based vaccination and prevention of type 1 diabetes.
    Harrison LC; Wentworth JM; Zhang Y; Bandala-Sanchez E; Böhmer RM; Neale AM; Stone NL; Naselli G; Bosco JJ; Auyeung P; Rashidi M; Augstein P; Morahan G
    Curr Diab Rep; 2013 Oct; 13(5):616-23. PubMed ID: 23888323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Arrest in the Progression of Type 1 Diabetes at the Mid-Stage of Insulitic Autoimmunity Using an Autoantigen-Decorated All-
    Phillips BE; Garciafigueroa Y; Engman C; Liu W; Wang Y; Lakomy RJ; Meng WS; Trucco M; Giannoukakis N
    Front Immunol; 2021; 12():586220. PubMed ID: 33763059
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The targeting of β-cells by T lymphocytes in human type 1 diabetes: clinical perspectives.
    Luce S; Briet C; Bécourt C; Lemonnier F; Boitard C
    Diabetes Obes Metab; 2013 Sep; 15 Suppl 3():89-97. PubMed ID: 24003925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging Therapeutic Strategies to Restore Regulatory T Cell Control of Islet Autoimmunity in Type 1 Diabetes.
    Volfson-Sedletsky V; Jones A; Hernandez-Escalante J; Dooms H
    Front Immunol; 2021; 12():635767. PubMed ID: 33815387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of the CamAPS FX hybrid closed-loop insulin delivery system on sleep traits in older adults with type 1 diabetes.
    Thabit H; Boughton C; Mubita W; Rubio J; Mader JK; Narendran P; Evans M; Leelarathna L; Wilinska ME; Fullwood C; Gregory AM; Hovorka R; Rutter MK
    Diabetes Obes Metab; 2023 Mar; 25(3):889-893. PubMed ID: 36335565
    [No Abstract]   [Full Text] [Related]  

  • 34. Proinsulin-a pathogenic autoantigen in type 1 diabetes.
    Narendran P; Mannering SI; Harrison LC
    Autoimmun Rev; 2003 Jun; 2(4):204-10. PubMed ID: 12848947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Old Dog New Tricks: PLGA Microparticles as an Adjuvant for Insulin Peptide Fragment-Induced Immune Tolerance against Type 1 Diabetes.
    Liu M; Feng D; Liang X; Li M; Yang J; Wang H; Pang L; Zhou Z; Yang Z; Kong D; Li C
    Mol Pharm; 2020 Sep; 17(9):3513-3525. PubMed ID: 32787283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new platform for autoimmune diseases. Inducing tolerance with liposomes encapsulating autoantigens.
    Almenara-Fuentes L; Rodriguez-Fernandez S; Rosell-Mases E; Kachler K; You A; Salvado M; Andreev D; Steffen U; Bang H; Bozec A; Schett G; Le Panse R; Verdaguer J; Dalmases M; Rodriguez-Vidal S; Barneda-Zahonero B; Vives-Pi M
    Nanomedicine; 2023 Feb; 48():102635. PubMed ID: 36481472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunomodulation with human recombinant autoantigens.
    Lernmark A; Agardh CD
    Trends Immunol; 2005 Nov; 26(11):608-12. PubMed ID: 16153889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Soluble Antigen Arrays for Selective Desensitization of Insulin-Reactive B Cells.
    Leon MA; Wemlinger SM; Larson NR; Ruffalo JK; Sestak JO; Middaugh CR; Cambier JC; Berkland C
    Mol Pharm; 2019 Apr; 16(4):1563-1572. PubMed ID: 30681867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of insulin pumps and closed-loop systems among people living with diabetes: A narrative review of clinical and cost-effectiveness to enable access to technology and meet the needs of payers.
    Jendle J; Reznik Y
    Diabetes Obes Metab; 2023 Jul; 25 Suppl 2():21-32. PubMed ID: 37046364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene therapy in type 1 diabetes.
    Bagley J; Paez-Cortez J; Tian C; Iacomini J
    Crit Rev Immunol; 2008; 28(4):301-24. PubMed ID: 19166382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.